Researchers report on the BRIGHT AML 1019 Phase III trial.
Researchers explore the predictive capability of EVI1 expression.
Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.
In this study, FLT3-IRAK1/4 inhibitor (NCGC1481) removed adaptively resistant FLT3-mutant AML cells.
The US Food and Drug Administration recently approved gilteritinib (Xospata), in addition to final trial data from the phase 3 ADMIRAL trial, making it the new standard of care for acute myeloid leukemia.
Researchers utilized a targeted next-generation sequencing (NGS) panel developed at Oregon Health & Science University to assess the clearance of mutations after therapy, clonal evolution at relapse, and combinations of mutations.
A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia.
With the exception of bladder cancer, the frequency of KDM6A gene mutations in malignancy is thought to be rather low in malignant developments.
A new suggests that the gene expression signature 4-GES, which consists of four genes (SOCS2, IL2RA, NPDC1, PHGDH), may be an independent prognostic factor in acute myeloid leukemia (AML).
The addition of sorafenib to intensive chemotherapy had a significant impact on the survival rate of patients with FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.